A new agreement between Allosteric Bioscience and Polaris Quantum Biotech paves the way for the discovery of new pharmaceuticals.
Allosteric Bioscience, a company founded last year to integrate quantum computing and AI with biomedical sciences to create improved treatments for aging and longevity, has signed a collaboration agreement with Polaris Quantum Biotech, a company at the forefront of quantum computing for drug discovery. Together, they are using advances in quantum computing and AI for the development of new pharmaceutical products.
Longevity.Technology: Quantum computing isn’t just fast computing: it’s computing jumped to another level (a quantum leap, if you will). Using quantum algorithms that exploit quantum entanglement, these powerful machines can create massive multidimensional spaces to represent complex problems, and thus solve these problems faster, more efficiently, and more elegantly than a standard classical computer.
Using qubits that have non-binary values (as opposed to the standard binary 0 and 1), quantum computers can analyze multiple options simultaneously, rather than just sequentially. The impact of quality control on longevity drug discovery will be incredibly disruptive, as it will be able to compare millions of complicated molecules at the same time, taking into account all the nuances of human biological systems. It’s no wonder biotech and biopharmaceutical companies are forging relationships with quality control companies.
The focus of this agreement is a leading program in Allosteric Bioscience that focuses on improving aging, longevity and age-related diseases that will be supported by an investment in Polarisqb. This joint program uses quantum computing (QC) and AI to create an inhibitor of a key protein involved in aging; this inhibitor could have numerous health benefits, in addition to tapping into a multi-billion dollar market. Allosteric Bioscience is using its “QAB” platform to integrate QC, AI, genetics, genomics, systems biology, epigenetics Y proteomicsas well as two aging platforms: ALT (aging longevity targets) and ALM (aging longevity modulators).
Dr. Shahar Keinan, CEO of Polarisqb, said: “Quantum computing technology is coming of age, allowing us to revolutionize drug discovery timelines, while improving the overall profile of designed drugs. . We are excited about the joint program with Allosteric addressing aging and longevity using Polarisqb’s Tachyon platform. The application of quantum computers to solve these complex questions is extraordinary. .”
Dr. Arthur P Bollon, President of Allosteric Bioscience, added: “The agreement between Allosteric Bioscience and Polarisqb represents an important milestone in the implementation of Allosteric Bioscience’s strategy of integrating the quantum computer and advanced AI with biomedical sciences for creation and development of advanced treatments for the improvement of Aging, longevity and age-related diseases .”
Polaris quantum biotechnology created the first quantum computer-based drug discovery platform. Founded in 2020 by Shahar Keinan, CEO, and Bill Shipman, CTO, Polarisqb uses the cloud, quantum computing, and machine learning to process, test, and identify lead molecules 10,000 times faster than alternative solutions. These selected lead drugs are synthesized, tested, and licensed to partners for development in months, rather than years. Information is available at
Allosteric Bioscience was founded by Bruce Meyers, Arthur P Bollon PhD, and Peter Sordillo PhD MD; all have years of experience in the biotechnology industry, as well as biomedical disciplines including genomics, epigenetics, systems biology, proteomics, oncology, and quantum physics. Meyers and Bollon founded several biotech companies, including Cytoclonal Pharmaceutics (Bollon served as chairman and CEO), which merged to create OPKO Health, a NASDAQ company with a market capitalization of $2 billion. Sordillo, who has a background in quantum information theory, is a leader in the treatment of sarcomas and other cancers and has directed more than 50 clinical trials at leading institutions, including the Sloan Kettering Cancer Center.